Literature DB >> 34889433

Upfront therapy: the case for continuous treatment.

Constantine S Tam1.   

Abstract

Both BTKi and BCL2i are regarded as standards of care for frontline treatment of CLL. In this paper, I present the arguments for favoring BTKi as initial therapy. Venetoclax-based regimens have the advantage of being fixed in duration, but patients with select high-risk features may experience inferior PFS relative to those without high-risk features.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34889433      PMCID： PMC8791150          DOI： 10.1182/hematology.2021000232

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  35 in total

1.  Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.

Authors:  Inhye E Ahn; Xin Tian; Adrian Wiestner
Journal:  N Engl J Med       Date:  2020-07-30       Impact factor: 91.245

2.  Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Authors:  Andrew W Roberts; Shuo Ma; Thomas J Kipps; Steven E Coutre; Matthew S Davids; Barbara Eichhorst; Michael Hallek; John C Byrd; Kathryn Humphrey; Lang Zhou; Brenda Chyla; Jacqueline Nielsen; Jalaja Potluri; Su Young Kim; Maria Verdugo; Stephan Stilgenbauer; William G Wierda; John F Seymour
Journal:  Blood       Date:  2019-04-25       Impact factor: 22.113

3.  ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  Paolo Ghia; Andrzej Pluta; Malgorzata Wach; Daniel Lysak; Tomas Kozak; Martin Simkovic; Polina Kaplan; Iryna Kraychok; Arpad Illes; Javier de la Serna; Sean Dolan; Phillip Campbell; Gerardo Musuraca; Abraham Jacob; Eric Avery; Jae Hoon Lee; Wei Liang; Priti Patel; Cheng Quah; Wojciech Jurczak
Journal:  J Clin Oncol       Date:  2020-05-27       Impact factor: 44.544

4.  Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Carol Moreno; Richard Greil; Fatih Demirkan; Alessandra Tedeschi; Bertrand Anz; Loree Larratt; Martin Simkovic; Olga Samoilova; Jan Novak; Dina Ben-Yehuda; Vladimir Strugov; Devinder Gill; John G Gribben; Emily Hsu; Chih-Jian Lih; Cathy Zhou; Fong Clow; Danelle F James; Lori Styles; Ian W Flinn
Journal:  Lancet Oncol       Date:  2018-12-03       Impact factor: 41.316

5.  Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.

Authors:  Anthony Mato; Chadi Nabhan; Neil E Kay; Nicole Lamanna; Thomas J Kipps; David L Grinblatt; Christopher R Flowers; Charles M Farber; Matthew S Davids; Pavel Kiselev; Arlene S Swern; Shriya Bhushan; Kristen Sullivan; E Dawn Flick; Jeff P Sharman
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-12-06

6.  Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  John F Seymour; Thomas J Kipps; Barbara Eichhorst; Peter Hillmen; James D'Rozario; Sarit Assouline; Carolyn Owen; John Gerecitano; Tadeusz Robak; Javier De la Serna; Ulrich Jaeger; Guillaume Cartron; Marco Montillo; Rod Humerickhouse; Elizabeth A Punnoose; Yan Li; Michelle Boyer; Kathryn Humphrey; Mehrdad Mobasher; Arnon P Kater
Journal:  N Engl J Med       Date:  2018-03-22       Impact factor: 91.245

7.  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

Authors:  Jeff P Sharman; Miklos Egyed; Wojciech Jurczak; Alan Skarbnik; John M Pagel; Ian W Flinn; Manali Kamdar; Talha Munir; Renata Walewska; Gillian Corbett; Laura Maria Fogliatto; Yair Herishanu; Versha Banerji; Steven Coutre; George Follows; Patricia Walker; Karin Karlsson; Paolo Ghia; Ann Janssens; Florence Cymbalista; Jennifer A Woyach; Gilles Salles; William G Wierda; Raquel Izumi; Veerendra Munugalavadla; Priti Patel; Min Hui Wang; Sofia Wong; John C Byrd
Journal:  Lancet       Date:  2020-04-18       Impact factor: 79.321

8.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

9.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

10.  Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.

Authors:  Susan M O'Brien; Samantha Jaglowski; John C Byrd; Rajat Bannerji; Kristie A Blum; Christopher P Fox; Richard R Furman; Peter Hillmen; Thomas J Kipps; Marco Montillo; Jeff Sharman; Sam Suzuki; Danelle F James; Alvina D Chu; Steven E Coutre
Journal:  JAMA Oncol       Date:  2018-05-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.